ConductScience.org, home

Comparison · NCT00986245-41f2ff2b

Once-daily of Ropinirole PR vs Twice-daily of Ropinirole PR: Patients Who Have Global Impression for Improvement

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Once-daily of Ropinirole PR vs Twice-daily of Ropinirole PR: Patients Who Have Global Impression for Improvement. Trial comparisons, record NCT00986245-41f2ff2b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00986245-41f2ff2b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5250.4020.645wilson
Risk in group 20.6890.5640.791wilson
Risk difference, group 1 minus group 2-0.164-0.3240.00901newcombe hybrid score
Risk ratio, group 1 over group 20.7620.5691.02log
Odds ratio, group 1 over group 20.4990.2381.05log
Number needed to treat, for one fewer participant with the outcome on Once-daily of Ropinirole PR than on Twice-daily of Ropinirole PR6.1from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Once-daily of Ropinirole PROnce-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.3261OG000
Group 2Twice-daily of Ropinirole PRTwice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.4261OG001

Outcome

Type
SECONDARY
Title
Patients Who Have Global Impression for Improvement
Description
Patients who have global impression for improvement for each dosing.
Time frame
After 8 weeks in each arm or at last visit for early completion
Population
The number of patient who completed the study and answered the questionnaire for global impression.

Source ClinicalTrials.gov

Trial

Title
Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily
NCT number
NCT00986245
Phases
PHASE4
Conditions
Parkinson Disease
Interventions
Ropinirole Prolonged release
Lead sponsor
Seoul National University Hospital
Results first posted
2013-09-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00986245-41f2ff2b